2021 was full of activity at Cumberland – and we’re especially proud to share several significant developments from a year that presented its share of challenges.

First, we nationally launched RediTrex®, our FDA-approved line of injectable methotrexate product for patients with arthritis. RediTrex enhances the effectiveness of arthritis treatments with stronger continuation rates and less discomfort. The pre-filled syringes assure accurate and safe dosing and have an automatic retractable, extra-thin 29-gauge needle to reduce pain and the risk of needle sticks. They also have a large grip and concave plunger that allow patients with limited dexterity to self-administer the injection at a controlled speed.

In November, we received FDA approval for use of our Caldolor® product, an intravenously delivered formulation of ibuprofen, prior to surgery. Orthopedic surgeon Dr. Stephen Southworth, who has published extensively on intravenous ibuprofen, supported this development, stating that “when administered immediately prior to surgery, patients given Caldolor experience less postoperative pain and a decrease in their opioid use.”

And, at the end of 2021, we signed an agreement with Japan-based Kyowa Kirin for the acquisition of the U.S. rights to their Sancuso® product. An oncology support drug, Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in cancer patients receiving certain chemotherapy treatments.

Other company highlights from 2021 include:

  • The issuance of our 2020 Sustainability Report, in which we detailed the company’s environmental, social and governance efforts. As noted in the report, we provided nearly 2.5 million patient doses of our products, safely disposed of over 4,000 pounds of expired and damaged products and had no recalls.


  • The announcement of our upcoming headquarters relocation to the new Broadwest campus in Nashville’s West End/Vanderbilt corridor later this year. The new space will allow us to continue to collaborate closely with the internationally recognized Vanderbilt University Medical Center.


  • The resumption of enrollment in our clinical studies, which had been interrupted during the pandemic. We’re currently sponsoring three Phase II clinical programs featuring our ifetroban product candidates. These studies involve patients with Duchenne Muscular Dystrophy, a genetic neuromuscular disease; Systemic Sclerosis, a debilitating autoimmune disorder; and Aspirin-Exacerbated Respiratory Disease, a severe form of asthma.

These accomplishments wouldn’t have been possible without our incredible team. Despite another difficult year of operating during a pandemic, everyone here remained steadfast in pursuit of our mission. This focus and dedication allowed our company to excel in the face of difficulty. It’s an honor to be part of such a group of people.

We’re encouraged to see the return to a more normal operating environment – and with the contributions from our new product, Sancuso, we expect to deliver strong growth in 2022. As always, we will keep you updated on our progress along the way.